Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1978 1
1979 1
1981 2
1982 3
1983 2
1986 5
1989 3
1990 1
1991 1
1992 1
1993 3
1994 3
1995 3
1996 2
1997 2
1998 3
1999 4
2000 3
2001 5
2002 6
2003 3
2004 4
2005 4
2006 2
2007 3
2008 2
2009 4
2010 7
2011 8
2012 9
2013 6
2014 7
2015 8
2016 6
2017 11
2018 10
2019 10
2020 13
2021 6
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Seymour JF, et al. Among authors: montillo m. N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976. N Engl J Med. 2018. PMID: 29562156 Free article. Clinical Trial.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Munir T, et al. Among authors: montillo m. Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13. Am J Hematol. 2019. PMID: 31512258 Free PMC article. Clinical Trial.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Seymour JF, Kipps TJ, Eichhorst BF, D'Rozario J, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Panchal A, Lu T, Wu JQ, Jiang Y, Lefebure M, Boyer M, Kater AP. Seymour JF, et al. Among authors: montillo m. Blood. 2022 Aug 25;140(8):839-850. doi: 10.1182/blood.2021015014. Blood. 2022. PMID: 35605176 Free PMC article. Clinical Trial.
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF. Kater AP, et al. Among authors: montillo m. J Clin Oncol. 2020 Dec 1;38(34):4042-4054. doi: 10.1200/JCO.20.00948. Epub 2020 Sep 28. J Clin Oncol. 2020. PMID: 32986498 Free PMC article. Clinical Trial.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Byrd JC, et al. Among authors: montillo m. N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31. N Engl J Med. 2014. PMID: 24881631 Free PMC article. Clinical Trial.
Duvelisib for the treatment of chronic lymphocytic leukemia.
Frustaci AM, Tedeschi A, Deodato M, Zamprogna G, Cairoli R, Montillo M. Frustaci AM, et al. Among authors: montillo m. Expert Opin Pharmacother. 2020 Aug;21(11):1299-1309. doi: 10.1080/14656566.2020.1751123. Epub 2020 Apr 15. Expert Opin Pharmacother. 2020. PMID: 32292084 Review.
Ibrutinib for the treatment of chronic lymphocytic leukemia.
Deodato M, Frustaci AM, Zamprogna G, Cairoli R, Montillo M, Tedeschi A. Deodato M, et al. Among authors: montillo m. Expert Rev Hematol. 2019 May;12(5):273-284. doi: 10.1080/17474086.2019.1597703. Epub 2019 Apr 11. Expert Rev Hematol. 2019. PMID: 30916599 Review.
Role of fludarabine in hematological malignancies.
Montillo M, Ricci F, Tedeschi A. Montillo M, et al. Expert Rev Anticancer Ther. 2006 Sep;6(9):1141-61. doi: 10.1586/14737140.6.9.1141. Expert Rev Anticancer Ther. 2006. PMID: 17020450 Review.
173 results